Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$4.30 USD
-0.24 (-5.29%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.30 USD
-0.24 (-5.29%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 6.90% and 86.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Editas (EDIT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses
by Zacks Equity Research
FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More
by Kinjel Shah
Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.
Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 172.5% upside potential for Fate Therapeutics (FATE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down -52.57% in 4 Weeks, Here's Why Fate Therapeutics (FATE) Looks Ripe for a Turnaround
by Zacks Equity Research
Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.